Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure - The DanAblate-HF Trial
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.
• HF patients with AF within the past 12 months
• HF is defined as all of the below (all must apply)
⁃ Clinically assessed Heart Failure with Reduced Ejection Fraction (HFrEF)
⁃ An indication for initiation or ongoing guideline directed medical therapy for HFrEF, according to current Heart Failure guidelines
⁃ LVEF \< 50% at any point during the past 12 months
• AF is defined as one or more of the following:
• A. Symptomatic AF, documented by ECG, Holter of CIED
• B. Asymptomatic AF with one or more of the following:
⁃ Clinical indication for rhythm or rate control (documented by ECG, telemetry, Holter, CIED)
⁃ ≥2 ECG detected AF episodes within 3 months (on separate dates)
⁃ Holter detected AF with a continuous duration of more than 6 hours
⁃ CIED detected AF with continuous duration \>24 hours
• 18 years ≤ Age \<80 years
• Optimal medical therapy for HFrEF or planned/current uptitration in guideline directed medical therapy for HFrEF
• Treatment with anticoagulation for stroke prevention, initiated according to guidelines for treatment of AF